Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over

Osteoporosis International

Volumn 24, Issue 9, 2013, Pages 2483-2492

  Roussy, J P ^a   Bessette, L ^b   Bernatsky, S ^c   Rahme, E ^d   Lachaine, J ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Biologic DMARD; Case control; Fracture; Nested; Osteoporosis; Rheumatoid arthritis; Risk

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BIOLOGICAL PRODUCT; CALCIUM; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; VITAMIN D;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ELBOW FRACTURE; FEMALE; FEMUR FRACTURE; FOREARM FRACTURE; FRAGILITY FRACTURE; HEALTH CARE UTILIZATION; HIP FRACTURE; HOSPITAL BILLING; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMERUS FRACTURE; ICD-10; ICD-9; MAJOR CLINICAL STUDY; MALE; NONVERTEBRAL OSTEOPOROSIS FRACTURE; NONVERTEBRAL OSTEOPOROTIC FRACTURE; PHYSICIAN; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; QUEBEC; RISK ASSESSMENT;

EID: 84881660060     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2321-x     Document Type: Article

References (45)

1. Redlich K, Smolen JS (2012) Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234-250
2. Vosse D, de Vlam K (2009) Osteoporosis in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27:S62-S67
3. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases - a case-control study with 53,108 patients with fracture. J Rheumatol 37:2247-2250
4. Wright NC, Lisse JR, Walitt BT, Eaton CB, Chen Z (2011) Arthritis increases the risk for fractures - results from the Women's Health Initiative. J Rheumatol 38:1680-1688
5. Michaud K, Wolfe F (2007) Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:885-906
6. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Bombardier C (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39:1559-1582
7. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353-357
8. Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA, Lems WF (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:389-390
9. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:330-336
10. Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898-1901
11. Hoff M, Kvien TK, Kalvesten J, Elden A, Kavanaugh A, Haugeberg G (2011) Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord 12:54
12. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61
13. Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN (2008) Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 27:795-797
14. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495-1499
15. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373-376
16. Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44:1546-1548
17. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M (2006) Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:420-427
18. RAMQ (2012). Régie de l'assurance maladie du Québec. Data and statistics (updated 2012). Available from http://www.ramq.gouv.qc.ca/en/ data-statistics/Pages/data-statistics.aspx. Accessed 1 Aug 2012
19. Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48:999-1009
20. Jean S, Candas B, Belzile E, Morin S, Bessette L, Dodin S, Brown JP (2012) Algorithms can be used to identify fragility fracture cases in physician-claims databases. Osteoporos Int 23:483-501
21. Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400-1405
22. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619
23. Leslie WD, Lix LM, Yogendran MS (2011) Validation of a case definition for osteoporosis disease surveillance. Osteoporos Int 22:37-46
24. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952-1960
25. Nikitovic M, Wodchis WP, Krahn MD, Cadarette SM (2013) Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int 24:659-669
26. Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581-593
27. Bessette L, Jean S, Lapointe-Garant MP, Belzile EL, Davison KS, Ste-Marie LG, Brown JP (2012) Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int 23:1757-1768
28. Cheng CK, McDonald-Blumer H, Boire G, Pope JE, Haraoui B, Hitchon CA, Thorne C, Sun Y, Bykerk VP (2010) Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX((R)). J Rheumatol 37:2221-2225
29. Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS (2006) Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum 55:873-877
30. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH (2010) Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12:R154
31. Vis M, Haavardsholm EA, Boyesen P, Haugeberg G, Uhlig T, Hoff M, Woolf A, Dijkmans B, Lems W, Kvien TK (2011) High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int 22:2413-2419
32. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 15:155-160
33. Kim SY, Schneeweiss S, Liu J, Solomon DH (2012) Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 27:789-796
34. Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53:241-248
35. Shipton D, Glazier RH, Guan J, Badley EM (2004) Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care 42:907-913
36. Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, Gunraj N, Bombardier C (2011) Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken) 63:53-57
37. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69-72
38. Lix LM, Azimaee M, Osman BA, Caetano P, Morin S, Metge C, Goltzman D, Kreiger N, Prior J, Leslie WD (2012) Osteoporosis-related fracture case definitions for population-based administrative data. BMC Publ Health 12:301
39. MacLean CH, Park GS, Traina SB, Liu HH, Hahn BH, Paulus HE, Kahn KL (2001) Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA) [abstract]. Arthritis & Rheum 44(S9):S106
40. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, Solomon DH (2011) Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 13:R32
41. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
42. Nampei A, Hashimoto J, Koyanagi J, Ono T, Hashimoto H, Tsumaki N, Tomita T, Sugamoto K, Nishimoto N, Ochi T, Yoshikawa H (2008) Characteristics of fracture and related factors in patients with rheumatoid arthritis. Mod Rheumatol 18:170-176
43. Romas E, Gillespie MT (2006) Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 32:759-773
44. Vinet E, Kuriya B, Widdifield J, Bernatsky S (2011) Rheumatoid arthritis disease severity indices in administrative databases: a systematic review. J Rheumatol 38:2318-2325
45. Leslie WD, Morin SN, Lix LM (2012) Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab 97:1211-1218